|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | One M Street, SE |
Address2 | Suite 510 |
| City | WASHINGTON |
State | DC |
Zip Code | 20003 |
Country | USA |
3. Principal place of business (if different than line 2)
| City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 69674-12
|
||||||||
|
6. House ID# 357890000
|
||||||||
| TYPE OF REPORT | 8. Year | 2024 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Bryant Robinson |
Date | 10/16/2024 4:25:08 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
Supporting the following funding levels in FY25 appropriations bills:
LHHS- $500 million for the Agency for Healthcare Research and Quality, $11.5 billion for the Centers for Disease Control and Prevention (inclusive of $5 million for the National Neurological Conditions Surveillance System), $20 million for the Lifespan Respite Care Program, Robust support for Medicare and Medicaid and protection of Medicaid's current financing structure, $51.3 billion for the National Institutes of Health, and at least $ 53.85 billion for the Indian Health Service.
DoD- $20 million for the MS Research Program and increased baseline funding of at least 5% plus inflation for the Congressionally Directed Medical Research Programs.
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense - Dept of (DOD), Food & Drug Administration (FDA), Veterans Affairs - Dept of (VA), Natl Institutes of Health (NIH)
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense - Dept of (DOD), Food & Drug Administration (FDA), Veterans Affairs - Dept of (VA), Natl Institutes of Health (NIH), Indian Health Service, Agency for Healthcare Research & Quality (AHRQ)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Bari |
Talente |
|
|
|
Nicole |
Boschi |
|
|
|
Bryant |
Robinson |
|
|
|
Steffany |
Stern |
|
|
|
Okey |
Enyia |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
S.652 - Safe Step Act (Murkowski/Hassan), support passage
H.R. 830 - HELP Copays Act, support passage
S.935- Fair Accountability and Innovative Research Drug Pricing Act of 2023, support passage
H.R. 485, Protecting Health Care For All Patients Act, oppose passage as currently written
S.127, the Pharmacy Benefit Manager Transparency Act, support passage
Urged HELP and House Energy and Commerce Committee to hold roundtables and advance proposals that address workforce issues within the healthcare community.
S. 2333 - Pandemic and All-Hazards Preparedness and Response Act, support passage
H.R. 824, Telehealth Benefit Expansion for Workers Act of 2023, oppose passage
H.R. 4421, Preparing for All Hazards and Pathogens Reauthorization Act, monitor legislation
H.R. 4420, Preparedness and Response Reauthorization Act, monitor legislation
Committee Draft -The Primary Care and Health Workforce Expansion Act, support passage
S. 1339, the Pharmacy Benefit Manager Reform Act, support passage
S.127, the PBM Transparency Act of 2023, support passage
S.113, The Prescription Pricing for the People Act of 2023, support passage
S.2052, Protect Patient Access to Pharmacies Act
H.R. 1692, Health Care Affordability Act of 2023
H.R. 3561, the PATIENT Act of 2023, support passage
H.R. 3284, Providers and Payers Compete Act, support passage
H.R. 4507, Transparency in Coverage Act, support passage
H.R. 4508, Hidden Fee Disclosure Act, support passage
H.R. 2816, PBM Sunshine and Accountability Act, support passage
S.79- Interagency Patent Coordination and Improvement Act of 2023, support passage
S. 142- Preserve Access to Affordable Generics and Biosimilars Act, support passage
S.148- Stop STALLING Act, support passage
S.150- Affordable Prescriptions for Patients Act of 2023, support passage
S.775-Increasing Transparency in Generic Drug Applications Act, monitoring
S.1067-Ensuring Timely Access to Generics Act of 2023, support passage
S. 2780 Medication Affordability and Patent Integrity Ac
H.R. 4189, the CONNECT for Health Act, support passage
H.R. 1843, the Telehealth Expansion Act, support passage
H.R. 8018, the Alleviating Barriers for Caregivers Act, support passage
S. 3109, the Alleviating Barriers for Caregivers Act, support passage
H.R.6302, the Health Share Transparency Act of 2023
H.R.7623, the Telehealth Modernization Act of 2024
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Food & Drug Administration (FDA), Health & Human Services - Dept of (HHS), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Nicole |
Boschi |
|
|
|
Bari |
Talente |
|
|
|
Bryant |
Robinson |
|
|
|
Steffany |
Stern |
|
|
|
Okey |
Enyia |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
S.1967, Patients Before Middlemen Act, support passage
S.2973, Modernizing and Ensuring PBM Accountability Act, support passage
S.2254, Medicare PBM Accountability Act, support passage
Support legislation that would impact Medicare/Medicaid health care costs through Pharmacy Benefit Manager (PBM) reform.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Office of Administration
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Bari |
Talente |
|
|
|
Nicole |
Boschi |
|
|
|
Steffany |
Stern |
|
|
|
Bryant |
Robinson |
|
|
|
Okey |
Enyia |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MED
16. Specific lobbying issues
S.79 - Interagency Patent Coordination and Improvement Act of 2023, support passage
S.113, the Prescription Pricing for the People Act of 2023,support passage
S.142, the Preserve Access to Affordable Generics and Biosimilars Act, support passage
S.148, the Stop Stalling Act, support passage
S.150, the Affordable Prescriptions for Patients Act of 2023, support passage
H.R.1114- Long COVID Recovery Now Act
S.801/H.S. 1616 CARE for Long COVID Act, support passage
The Biosimilar Red Tape Elimination Act, monitor legislation
U.S. HOUSE OF REPRESENTATIVES, U.S. Senate, Natl Institutes of Health (NIH), Defense - Dept of (DOD), Food & Drug Administration (FDA), Veterans Affairs - Dept of (VA)
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), Defense - Dept of (DOD), Food & Drug Administration (FDA), Veterans Affairs - Dept of (VA), U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Nicole |
Boschi |
|
|
|
Bryant |
Robinson |
|
|
|
Bari |
Talente |
|
|
|
Steffany |
Stern |
|
|
|
Okey |
Enyia |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
TRA |
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
| Lobbyist Name | Description of Offense(s) |